|
US6723832B1
(en)
*
|
1996-10-03 |
2004-04-20 |
Ludwig Institute For Cancer Research |
Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
|
|
US6417165B1
(en)
|
1988-03-27 |
2002-07-09 |
Ludwig Institute For Cancer Research |
NY-ESO-1-peptide derivatives, and uses thereof
|
|
US6252052B1
(en)
*
|
1996-10-03 |
2001-06-26 |
Cornell Research Foundation, Inc |
Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
|
|
US6251603B1
(en)
|
1996-10-03 |
2001-06-26 |
Ludwig Institute For Cancer Research |
Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
|
|
US7888100B2
(en)
*
|
1996-10-03 |
2011-02-15 |
Memorial Sloan-Kettering Cancer Research |
Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
|
|
US6255470B1
(en)
*
|
1996-10-03 |
2001-07-03 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
|
|
PT970206E
(pt)
|
1997-01-27 |
2008-10-28 |
Ludwig Inst Cancer Res |
Ácidos nucleicos lage-1 associados a tumores
|
|
US6794131B1
(en)
|
1998-01-27 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Lage-1 tumor associated nucleic acids
|
|
US6287756B1
(en)
|
1997-05-05 |
2001-09-11 |
Ludwig Institute For Cancer Research |
Methods for determining presence of cancer in a sample by determining expression of an SSX gene
|
|
US6673350B2
(en)
*
|
1997-05-05 |
2004-01-06 |
Ludwig Institute For Cancer Research |
Tumor associated peptide and uses thereof
|
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US7084239B1
(en)
|
1997-10-08 |
2006-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cancer peptides of NY-ESO-1/CAG-3
|
|
WO1999018206A2
(en)
*
|
1997-10-08 |
1999-04-15 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Human cancer antigen ny eso-1/cag-3 and gene encoding same
|
|
EP1806403A3
(en)
*
|
1997-10-08 |
2008-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
|
|
US7001999B1
(en)
*
|
1998-04-15 |
2006-02-21 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
|
US6140050A
(en)
*
|
1998-06-26 |
2000-10-31 |
Ludwig Institute For Cancer Research |
Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
|
|
US6800730B1
(en)
*
|
1998-10-02 |
2004-10-05 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to MHC class II molecules, and uses thereof
|
|
WO2000050595A2
(en)
*
|
1999-02-25 |
2000-08-31 |
Ivan Gout |
Nucleic acid molecules associated with melanoma and thyroid tumors
|
|
DE19949595A1
(de)
*
|
1999-10-14 |
2001-05-03 |
Deutsches Krebsforsch |
CTAGE-Genfamilie
|
|
JP4540033B2
(ja)
|
1999-10-22 |
2010-09-08 |
サノフィ パストゥール リミテッド |
腫瘍抗原に対する免疫応答を誘発および／または増強する方法
|
|
US6689742B1
(en)
*
|
2000-02-25 |
2004-02-10 |
Chancellors, Masters And Scholars Of The University Of Oxford |
NY-ESO-1 peptide derivatives, and uses thereof
|
|
AU2001250828A1
(en)
*
|
2000-03-14 |
2001-09-24 |
The Johns Hopkins University School Of Medicine |
Immunogenic ovarian cancer genes
|
|
US6861234B1
(en)
|
2000-04-28 |
2005-03-01 |
Mannkind Corporation |
Method of epitope discovery
|
|
EP1752160A3
(en)
|
2001-04-06 |
2007-05-30 |
Mannkind Corporation |
Epitope sequences
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
WO2002086071A2
(en)
*
|
2001-04-20 |
2002-10-31 |
Ludwig Institute For Cancer Research |
Cancer-testis antigens
|
|
US6794501B2
(en)
*
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
|
US7803382B2
(en)
*
|
2001-05-04 |
2010-09-28 |
Ludwig Institute For Cancer Research Ltd. |
Method for inducing immune response to NY-CO-58
|
|
EP1453471B1
(en)
|
2001-11-07 |
2011-01-05 |
Mannkind Corporation |
Expression vectors encoding epitopes of antigens and methods for their design
|
|
NZ535425A
(en)
*
|
2002-03-13 |
2008-05-30 |
Biogen Idec Inc |
Anti-alphavbeta6 antibodies
|
|
CN1691964A
(zh)
*
|
2002-09-06 |
2005-11-02 |
曼康公司 |
表位序列
|
|
WO2005000870A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Ludwig Institute Of Cancer Research |
Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
|
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
|
WO2004112825A2
(en)
|
2003-06-17 |
2004-12-29 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
WO2005114203A2
(en)
*
|
2004-05-20 |
2005-12-01 |
The Regents Of The University Of California |
Dominant b cell epitopes and methods of making and using thereof
|
|
US20060008468A1
(en)
*
|
2004-06-17 |
2006-01-12 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
US8354380B2
(en)
|
2004-06-17 |
2013-01-15 |
Mannkind Corporation |
NY-ESO-1 peptide analogs
|
|
US20060159689A1
(en)
*
|
2004-06-17 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
AU2005321904B2
(en)
*
|
2004-12-29 |
2012-07-12 |
Mannkind Corporation |
Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
|
|
JP2008526760A
(ja)
|
2004-12-29 |
2008-07-24 |
マンカインド コーポレイション |
種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
|
|
US7999088B2
(en)
|
2005-06-17 |
2011-08-16 |
Mannkind Corporation |
Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
|
|
WO2006138568A2
(en)
|
2005-06-17 |
2006-12-28 |
Mannkind Corporation |
Multivalent entrain-and-amplify immunotherapeutics for carcinoma
|
|
NZ564359A
(en)
|
2005-06-17 |
2011-09-30 |
Mannkind Corp |
Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US8309096B2
(en)
*
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
DK2224954T3
(en)
|
2007-11-07 |
2014-03-03 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
CA2717499A1
(en)
|
2008-03-14 |
2009-09-17 |
Sanofi Pasteur Biologics Co. |
Replication-defective flavivirus vaccines and vaccine vectors
|
|
BRPI1009873A2
(pt)
|
2009-03-17 |
2016-03-08 |
Glaxosmithkline Biolog Sa |
detecção aperfeiçoada de expressão gênica
|
|
GB0910046D0
(en)
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
PT3892295T
(pt)
|
2011-05-24 |
2023-06-01 |
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh |
Vacinas individualizadas para o cancro
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
US8490054B2
(en)
|
2011-09-23 |
2013-07-16 |
The United States Of America As Represented By The Secretary Of The Army |
Software and related software tracking during software modification
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
EP4483965A3
(en)
|
2012-11-28 |
2025-04-02 |
BioNTech SE |
Individualized vaccines for cancer
|
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
CA2951234C
(en)
|
2014-06-06 |
2022-05-31 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
EP3194970B1
(en)
|
2014-09-10 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Immunogenic mutant peptide screening platform
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
MX393066B
(es)
|
2016-04-18 |
2025-03-24 |
Celldex Therapeutics Inc |
Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
|
|
NL2018803B1
(en)
|
2017-04-27 |
2018-11-05 |
Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc |
Adjuvant compounds
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
IL293698A
(en)
|
2019-12-11 |
2022-08-01 |
Molecular Partners Ag |
Recombinant peptide-mhc complex binding proteins, their production and use
|